Find Clinical Trial

Home » Find Clinical Trials » Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). – PERFORM

Prevention of cerebrovascular and cardiovascular Events of ischaemic origin with teRutroban in patients with a history oF ischaemic strOke or tRansient ischaeMic attack. The PERFORM Study. An international, randomised, double-blind, two parallel group study comparing terutroban 30 mg o.d. versus aspirin 100 mg o.d. administered orally for a 3-year mean duration (event driven trial). – PERFORM

← Back

Study Phase	Phase 3

Therapeutic Area	Cardiovascular Diseases

Indication	Stroke

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	TERUTROBAN, S018886

Active Substance Code	S018886

Protocol Code	CL3-18886-012

EudraCT Code	2005-003700-10

ISRCTN Code	ISRCTN66157730

Documents and links

Results summary	READ MORE

Scientific publication	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.